SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Company Overview - SCYNEXIS, Inc. is a biotechnology company focused on developing innovative medicines to combat difficult-to-treat and drug-resistant infections [3] - The company is advancing its proprietary antifungal platform known as "fungerps" [3] - Ibrexafungerp, the first drug from this novel class, has been licensed to GSK and received FDA approval for vulvovaginal candidiasis in June 2021, with a second indication approved in November 2022 [3] Upcoming Event - David Angulo, M.D., President and CEO of SCYNEXIS, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024, at 11:30 A.M. ET [1] - The event will be held virtually, and investors can sign up to view the presentation [1] Clinical Development - Late-stage clinical investigations of ibrexafungerp for treating life-threatening invasive fungal infections in hospitalized patients are currently ongoing [3] - Additional antifungal compounds from the same class, including SCY-247, are in pre-clinical and discovery phases [3]